Journal
INVESTIGATIONAL NEW DRUGS
Volume 21, Issue 1, Pages 99-101Publisher
KLUWER ACADEMIC PUBL
DOI: 10.1023/A:1022928612511
Keywords
renal cell carcinoma; Cetuximab; C225; monoclonal antibody
Categories
Ask authors/readers for more resources
Fifty-five patients with metastatic renal cell carcinoma (RCC) were treated on a multicenter, single-arm Phase II trial. Patients received single-agent Cetuximab (C225) administered by intravenous infusion at a loading dose of 400 or 500 mg/m(2) followed by weekly maintenance doses at 250 mg/m2. None of the patients treated with C225 achieved either a complete or partial response. The median time to progression was 57 days. The most frequently reported grade 3 or 4 toxicity treatment-related adverse events were acne (17%) and rash or dry skin (4%). The lack of clinical response or suggestion of prolonging time to progression compared to historical data with interferon-alfa supports no further study of single-agent C225 in patients with metastatic RCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available